Drug Trial Radar · NCT06169397
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Mar 1, 2024
Primary completion
Oct 9, 2026
Study completion Oct 9, 2026
Sponsor
- Lead sponsor
- Xentria, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
Conditions
- Pulmonary Sarcoidosis
Interventions
XTMAB-16Drug
XTMAB-16 infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), and Adverse Events of Special Interests (AESIs) throughout the study durationTime frame: Through study completion, an average of 4 years
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Xentria Investigative Site
Denver, Colorado
Xentria Investigative Site
Chicago, Illinois
Xentria Investigative Site
Greenville, North Carolina
Xentria Investigative Site
Cincinnati, Ohio
Xentria Investigative Site
Philadelphia, Pennsylvania
Xentria Investigative Site
Prague, Czechia
Xentria Investigative Site
Bielsk Podlaski, Poland
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, England, United Kingdom
King's College Hospital NHS Foundation Trust
London, England, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich, England, United Kingdom
NHS Tayside
Perth, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.